115TH CONGRESS 
1ST SESSION 
H. R. 309 
AN ACT 
To amend the Public Health Service Act to foster more 
effective implementation and coordination of clinical care 
for people with a complex metabolic or autoimmune dis-
ease, a disease resulting from insulin deficiency or insulin 
resistance, or complications caused by such a disease, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘National Clinical Care 
Commission Act’’. 
SEC. 2. ESTABLISHMENT OF A NATIONAL CLINICAL CARE 
COMMISSION. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following new section: 
‘‘SEC. 399V–7. NATIONAL CLINICAL CARE COMMISSION. 
‘‘(a) ESTABLISHMENT.—There is hereby established, 
within the Department of Health and Human Services, 
a National Clinical Care Commission (in this section re-
ferred to as the ‘Commission’) to evaluate, and rec-
ommend solutions regarding better coordination and 
leveraging of, programs within the Department and other 
Federal agencies that relate in any way to supporting ap-
propriate clinical care (such as any interactions between 
physicians and other health care providers and their pa-
tients related to treatment and care management) for indi-
viduals with— 
‘‘(1) one or more complex metabolic or auto-
immune diseases; 
‘‘(2) one or more diseases resulting from insulin 
deficiency or insulin resistance; or 
‘‘(3) complications caused by one or more of 
any of such diseases.
‘‘(b) MEMBERSHIP.— 
‘‘(1) IN GENERAL.—The Commission shall be 
composed of the following voting members: 
‘‘(A) The heads (or their designees) of the 
following Federal agencies and departments: 
‘‘(i) The Centers for Medicare & Med-
icaid Services. 
‘‘(ii) The Agency for Healthcare Re-
search and Quality. 
‘‘(iii) The Centers for Disease Control 
and Prevention. 
‘‘(iv) The Indian Health Service. 
‘‘(v) The Department of Veterans Af-
fairs. 
‘‘(vi) The National Institutes of 
Health. 
‘‘(vii) The Food and Drug Adminis-
tration. 
‘‘(viii) The Health Resources and 
Services Administration. 
‘‘(ix) The Department of Defense. 
‘‘(B) Twelve additional voting members ap-
pointed under paragraph (2). 
‘‘(C) Such additional voting members as 
may be appointed by the Secretary, at the Sec-
retary’s discretion, from among the heads (or 
their designees) of governmental or nongovern-
mental entities that impact clinical care of indi-
viduals with any of the diseases and complica-
tions described in subsection (a). 
‘‘(2) ADDITIONAL MEMBERS.—The Commission 
shall include additional voting members appointed by 
the Secretary, in consultation with national medical 
societies and patient advocacy organizations with ex-
pertise in the care and epidemiology of any of the 
diseases and complications described in subsection 
(a), including one or more such members from each 
of the following categories: 
‘‘(A) Clinical endocrinologists. 
‘‘(B) Physician specialties (other than as 
described in subparagraph (A)) that play a role 
in diseases and complications described in sub-
section (a), such as cardiologists, nephrologists, 
and eye care professionals. 
‘‘(C) Primary care physicians. 
‘‘(D) Non-physician health care profes-
sionals, such as certified diabetes educators, 
registered dieticians and nutrition professionals, 
nurses, nurse practitioners, physician assist-
ants.
‘‘(E) Patient advocates. 
‘‘(F) National experts in the duties listed 
under subsection (c). 
‘‘(G) Health care providers furnishing 
services to a patient population that consists of 
a high percentage (as specified by the Sec-
retary) of individuals who are enrolled in a 
State plan under title XIX of the Social Secu-
rity Act or who are not covered under a health 
plan or health insurance coverage. 
‘‘(3) CHAIRPERSON.—The voting members of 
the Commission shall select a chairperson from the 
members appointed under paragraph (2) from the 
category under paragraph (2)(A). 
‘‘(4) MEETINGS.—The Commission shall meet 
at least twice, and not more than four times, a year. 
‘‘(5) BOARD TERMS.—Members of the Commis-
sion appointed pursuant to subparagraph (B) or (C) 
of paragraph (1), including the chairperson, shall 
serve for a 3-year term. A vacancy on the Commis-
sion shall be filled in the same manner as the origi-
nal appointments. 
‘‘(c) DUTIES.—The Commission shall— 
‘‘(1) evaluate programs of the Department of 
Health and Human Services regarding the utiliza-
tion of diabetes screening benefits, annual wellness 
visits, and other preventive health benefits that may 
reduce the incidence of the diseases and complica-
tions de scribed in subsection (a), including identi-
fying problems regarding such utilization and related 
data collection mechanisms and make recommenda-
tions; 
‘‘(2) identify current activities and critical gaps 
in Federal efforts to support clinicians in providing 
integrated, high-quality care to individuals with any 
of the diseases and complications described in sub-
section (a); 
‘‘(3) make recommendations regarding the co-
ordination of clinically based activities that are being 
supported by the Federal Government with respect 
to the diseases and complications described in sub-
section (a); 
‘‘(4) make recommendations regarding the de-
velopment and coordination of federally funded clin-
ical practice support tools for physicians and other 
health care professionals in caring for and managing 
the care of individuals with any of the diseases and 
complications described in subsection (a), specifically 
with regard to implementation of new treatments 
and technologies;
‘‘(5) evaluate programs described in subsection 
(a) that are in existence as of the date of the enact-
ment of this section and determine if such programs 
are meeting the needs identified in paragraph (2) 
and, if such programs are determined as not meet-
ing such needs, recommend programs that would be 
more appropriate; 
‘‘(6) recommend, with respect to the diseases 
and complications described in subsection (a), clin-
ical pathways for new technologies and treatments, 
including future data collection activities, that may 
be developed and then used to evaluate— 
‘‘(A) various care models and methods; 
and 
‘‘(B) the impact of such models and meth-
ods on quality of care as measured by appro-
priate care parameters (such as A1C, blood 
pressure, and cholesterol levels); 
‘‘(7) evaluate and expand education and aware-
ness activities provided to physicians and other 
health care professionals regarding clinical practices 
for the prevention and treatment of the diseases and 
complications described in subsection (a);